Private-Label Heat Patches: US Buyer Guide

Define a US heat-patch SKU, review claims and plan a supervised, non-human bench comparison before private-label artwork and production.

Start With Product Identity, Not a Two-Path Shortcut

FDA’s own guidance says the device determination turns on intended use — what the product is for, as shown by its labeling, claims, and marketing [2]. Concretely for this category:

• The FDA product classification database includes an entry for chemical heat packs for temporary relief of pain (product code OMW) [1]. The existence of this entry shows that a heat patch is not automatically an ordinary consumer good: position a patch for pain relief and you may be in device territory.
• For a product that is not a medical device, other federal, state, import, labeling, and consumer-product obligations may still apply. The applicable set depends on the actual SKU and market; 16 CFR Chapter II is a regulatory starting point, not a classification decision [3].

“Not a medical device” is not “unregulated.” Do not infer a complete compliance route from a product photo, a factory statement, or the absence of a pain-relief claim. The temperature protocol below is only a buyer-side incoming-sample comparison; it cannot establish thermal-injury safety, skin-contact safety, biocompatibility, regulatory compliance, or market admissibility.

The practical workflow for a private-label line: lock the product definition first — formula and heating mechanism, skin-contact design, label copy, and a written claims inventory (every sentence your packaging and listings will say). Then run FDA’s determination logic per SKU [2], or engage a regulatory consultant for borderline cases. Do this before artwork is printed; changing the route after packaging is produced creates avoidable rework and inventory risk.

One more boundary worth stating: air-activated patches in the consumer channel also carry ordinary import attributes. The leading US brand’s published specification, for example, lists Harmonized Code 3005.90.9900 and ECCN EAR99 for its hand warmers [4] — a useful reference point for broker conversations, though your classification must be confirmed for your product, not copied.

Temperature Performance: A Public Reference, Not a Benchmark

For context only, one named HotHands hand-warmer product publishes the following specifications. A hand warmer is not automatically equivalent to an adhesive skin patch, so these figures must not become a benchmark, acceptance limit, or safety target for another product:

These are competitor-published figures, not a safety limit and not a specification your supplier inherits. Compare your supplier’s samples against an agreed purchase specification, but do not turn a comparison result into a safety claim. Any herbal addition must be declared and reviewed with the complete formula, skin-contact design, intended use, and claims; composition is not a marketing detail.

Supervised, Non-Human Bench Comparison

Use this only as a commercial incoming-sample comparison on production-representative units. It is a supervised, non-human bench procedure: use a sensor suitable for the temperature range and contact method, with current calibration evidence, plus a non-human fixture defined in the buyer’s quality plan. Do not use human skin, customer wear, patient use, or any clinical setting as a screen. This is not safety, biocompatibility, thermal-injury, or regulatory testing.

1. Define the bench plan. Record sample IDs, batch codes, sensor identity and calibration status, non-human fixture, operator, ambient conditions, observation points, and stop conditions before activation.
2. Use an appropriate non-human fixture. Position the sensor and product only as the written bench plan specifies. Do not place a patch on a person or infer skin-contact safety from a fixture result.
3. Record the curve. Log the buyer-defined activation, time-to-peak, peak, sustained-temperature, and duration observations with the specified sensor and method.
4. Apply stop conditions. Stop and isolate the unit if there is unexpected leakage, rupture, smoke, deformation, an abnormal odor, a sensor fault, or any condition outside the documented observation plan. Escalate the record to the supplier and qualified reviewer; do not continue to obtain a curve.
5. Repeat as the quality plan requires. Compare multiple units and batches when available; a small comparison is not a statistical proof of production consistency.
6. Record non-human integrity observations. Note packaging damage, leakage, and output irregularity. Do not convert adhesion or fixture observations into skin-contact safety evidence.
7. Use buyer-defined commercial criteria carefully. An agreed comparison band and method may belong in a purchase specification, but they do not replace legally required testing or a product-safety assessment.

Labeling Implications by Path

Because labeling and claims are regulatory inputs, treat label copy as a regulated artifact, not marketing collateral. The points below are a scoping checklist, not a complete US compliance determination:

• Non-device scenario: identify the applicable consumer-product, import, labeling, and state requirements for the actual SKU before print. Do not rely on a generic CPSC reference as a complete checklist [3].
• FDA-device scenario: if a product-specific review places the SKU in an FDA device category, establish the applicable device obligations before launch [1][2].
• Claims inventory: preserve every proposed package, listing, and advertising claim in one review file. A warmth-oriented statement and a pain-relief statement can lead to different product analyses; do not assume wording alone settles the outcome.

The Supplier Documentation Package

Before the first production run, assemble a documentation package from your supplier that lets every later decision be made from records rather than assurances. For this category it has five components:

1. Composition declaration. The full fill list — iron, carbon, salt, binder, any herbal additions — with percentages or ranges. This feeds your broker conversation, your regulatory determination [2], and your own label accuracy.
2. Factory temperature records. The factory’s own curve data per batch (activation, peak, duration), which you then spot-verify with the protocol above. Records you can audit beat certificates you cannot.
3. Batch traceability. A batch-coding scheme that ties shipped cartons to production runs — the thing you will need the first time a customer reports an underperforming unit.
4. Packaging and instruction drafts. The factory’s default artwork and instruction text, so your regulatory review [2][3] works on the real artifact rather than a description of it.
5. Change-notification commitment. A contractual clause requiring advance notice of any formula, material, or process change. In a category where composition drives regulatory analysis, a silent formula change is a compliance event, not a quality footnote.

Make these requests part of your RFQ and record what the supplier can and cannot provide. A document set is an input to qualification; it does not by itself prove product safety, compliance, manufacturing capability, or final market admissibility.